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this goal. However, as funding for Quality Protects and
Children First is mainstreamed in 2004, primary care
trusts will need to show their commitment to invest in
the future health of looked after children—otherwise
the vision may prove to be only a mirage.
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Tobacco, coffee, and Parkinson’s disease
Caffeine and nicotine may improve the health of dopaminergic systems
Parkinson’s disease belongs to that small groupof conditions that occur less often amongcigarette smokers than in non-smokers. The
observation was first made in a case-control study over
30 years ago,1 but, as Hernán and colleagues have
shown in their recent systematic review and meta-
analysis,2 the finding has been replicated many times.
The protective effect is large—according to the pooled
data, current smokers have a 60% reduction in risk
compared with those who have never smoked—and
consistent between studies in different settings. The
fact that two very large prospective studies found a
similar reduction in risk to that seen in retrospective
studies rules out the possibility that the association can
be accounted for by differential survival between
smokers and non-smokers.3 Coffee drinking too, seems
to protect against Parkinson’s disease. Here the pooled
estimate is a 30% reduction in risk for coffee drinkers
compared with non-drinkers.
In “An Essay on the Shaking Palsy,” James
Parkinson noted that his first case “had industriously
followed the business of a gardener, leading a life of
remarkable temperance and sobriety.” Since then
several small studies have implied that people with
Parkinson’s disease tend to exhibit traits such as inflex-
ibility, cautiousness, and lack of novelty seeking even
before they have developed motor symptoms.4 5 This
idea has never been tested in a large prospective study,
but it does raise the possibility that people who will
later develop Parkinson’s disease are constitutionally
less likely to feel the need for the type of stimulation
provided by tobacco and coffee. This might occur if the
genetic determinants of likelihood and intensity of
behaviours such as cigarette smoking and coffee drink-
ing were the same as or closely linked to the genes that
determined susceptibility to Parkinson’s disease. If so,
any apparent protective effect might be the result of
confounding. The authors of the systematic review
explored this possibility in a sensitivity analysis. They
made the fairly extreme assumption that such a genetic
combination was present in a third of the population
and conferred both a fivefold increase in risk of
Parkinson’s disease and, simultaneously, a fivefold
decrease in likelihood of taking up smoking. Even after
adjusting for a genetic influence of this strength, smok-
ing still conferred more than a 30% reduction in risk.
If confounding by a genetic haplotype looks
unlikely, what other reasons remain? A theoretical
possibility is that the relation between cigarette
smoking or coffee drinking and Parkinson’s disease is
operating in the reverse direction. In other words,
Parkinson’s disease makes people less likely to smoke
or drink coffee. Of course these habits are usually
acquired by early adult life, whereas symptoms of
Parkinson’s disease are rare before late middle age. So
this explanation could be correct only if the subclinical
phase of the disease is very much longer than we
currently believe.
Perhaps it is more plausible that substances present
in coffee and tobacco—caffeine and nicotine are
obvious candidates—have a central action that
improves the health of dopaminergic systems. Evi-
dence in support of caffeine’s role as a neuroprotect-
ant has recently emerged from a study using a mouse
model of Parkinson’s disease. Mice that were
pretreated with caffeine before exposure to the
dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) lost less striatal dopamine
and fewer dopamine transporter binding sites.6
Caffeine’s apparent neuroprotective effect may be due
to its ability to block adenosine A2A receptors that are
concentrated in the dopamine rich areas of the brain.7
Adenosine decreases dopaminergic neurotransmis-
sion by means of antagonistic interactions between A2A
receptors and dopamine receptors.8 The blockade of
these receptors can therefore facilitate dopaminergic
transmission by stimulating dopamine release and by
potentiating the effects of dopamine receptor stimula-
tion. Knockout mice that lack functional adenosine A2A
receptors are also resistant to the dopamine depleting
effects of MPTP.6
Like caffeine, nicotine has been found to reduce
MPTP-induced dopaminergic toxicity in animal mod-
els of Parkinson’s disease.9 10 One mechanism under-
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lying this protective action may be its ability to increase
the expression of neurotrophic factors that are known
to promote survival of dopaminergic neurons.9 But
tobacco contains numerous other chemicals whose
influence on biological processes may play a part.
Smoking causes a reduction in activity of monoamine
oxidase A and B, for example, which might protect
against neuronal damage by inhibiting the enzymatic
oxidation of dopamine.11
One unachieved goal in the treatment of
Parkinson’s disease is preventing it getting worse. If, as
the epidemiological evidence implies, caffeine and
nicotine are neuroprotective, some of the new
pharmacological treatments currently being devel-
oped, such as adenosine A2A receptor blockers and
nicotinic agonists, might not only improve symptoms
but slow the relentless progression of the disease.
Christopher Martyn clinical scientist
Chris Gale senior research fellow
MRC Environmental Epidemiology Unit, Southampton General
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Massage treatment for back pain
Evidence for symptomatic relief is encouraging but not compelling
Throughout history different forms of massagetreatment have been used in all medicalcultures to alleviate a wide range of symptoms.
This article focuses on the most common form, classic
muscular (Swedish) massage, as a symptomatic
treatment for back pain.1 It will define the therapeutic
modality, review the evidence for or against effective-
ness and safety, and discuss possible mechanisms of
action as well as the problems of conducting research
in this area.
Swedish massage is a touch therapy that uses a
range of techniques to manipulate the soft tissues of
the body: effleurage (slow rhythmic stroking), kneading
(circular compression), petrissage (forceful skin roll-
ing), friction (penetrating pressure from the fingertips
with circular or transverse movement), tapotement
(percussive movements), vibration (trembling move-
ment of both hands).2 In most English speaking coun-
tries, massage is seen as an alternative or complemen-
tary treatment,3 whereas on the European continent it
is considered a conventional treatment, particularly for
back pain. In Austria, for example, 87% of patients with
back pain receive (and are usually reimbursed for)
massage treatment.4
A recent Cochrane review of massage treatment for
back pain summarised five randomised clinical trials
on the subject, three of which were of high
methodological quality.5 One study compared massage
with detuned laser therapy as placebo, and the other
trials compared massage with various other physical
treatments such as acupuncture or spinal manipu-
lation. The review shows that massage is superior to
placebo, relaxation treatment, acupuncture, or self care
education; inferior to manipulation, shiatsu, or
transcutaneous electrical stimulation; and no different
from treatment with corsets or exercise. The benefit
lasted at least one year. The authors concluded that
massage “might” be beneficial for subacute and
chronic non-specific low back pain.5 In a further
relevant trial, patients with “non-inflammatory rheu-
matic pain” (not just back pain) were randomised to
receive either 10 sessions of classic massage or usual
medical care for five weeks.6 By the end of this period,
both groups had improved similarly, and at three
months’ follow up more pain relief had occurred in the
massage group.
These studies are not easy to interpret. Some are
methodologically weak; most used control interven-
tions with uncertain effectiveness; some tested massage
other than Swedish massage; some allowed concomi-
tant interventions; and one trial6 was not conducted
exclusively on patients with back pain. Back pain is not
a disease entity but a symptom, and future studies
should aim at determining whether certain types of
patients respond better than others. The overall picture
that seems to emerge implies that the evidence for
massage as a symptomatic relief of back pain is
encouraging but not compelling.3 Similar conclusions
would be reached if one looked at other conditions for
which massage has been tested in controlled clinical
trials.3
Most massage therapists are convinced that
massage treatment is free of risk. This is not true. Too
much force can cause fractures of osteoporotic bones;
and even rupture of the liver and damage to nerves
have been associated with massage.7 These events are
rarities and massage is relatively safe, provided that well
trained therapists observe the contraindications:
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